Association Between Treatment Delivered After PET and Survival in 63 Patients with Suspected Relapse of NSCLC
| Group | No. of patients | Hazard ratio | 95% CI | P* |
|---|---|---|---|---|
| Specific treatment | ||||
| None | 15 | 1.00 | ||
| cSx | 4 | 1.55 | 0.28–8.47 | |
| rRT | 11 | 0.54 | 0.10–2.95 | |
| pRT | 15 | 3.76 | 1.19–11.8 | |
| pCT | 7 | 3.23 | 0.80–13.1 | |
| Supportive | 9 | 1.98 | 0.49–7.93 | 0.032 |
| Treatment intent | ||||
| None | 15 | 1.00 | ||
| Curative | 15 | 0.80 | 0.20–3.21 | |
| Palliative | 22 | 3.63 | 1.19–11.0 | |
| Supportive | 9 | 1.98 | 0.49–7.93 | 0.011 |
↵* Based on 2-sided tests.
cSx = surgery with curative intent; rRT = radical therapy combined with concurrent chemotherapy unless contraindicated; pRT = palliative radiotherapy; pCT = palliative chemotherapy.
Data on treatment given after PET exclude 2 patients who did not receive planned pRT. “Supportive” refers to delay in active management until dictated by symptomatic progression.